Slots in Snail Trail | Image Hosting


© 1997 by Ralph W. Moss, Ph.D.

A well-respected oncologist has concluded that the effects of Dr. Stanislaw R. Burzynski's antineoplaston treatment for brain cancer are "astounding" and need to be intensively investigated.

The doctor is Robert E. Burdick, M.D., who has been in the private practice of medical oncology in Seattle, WA for the last 27 years. He is a faculty member of the University of Washington and participates in cancer research in that state. He made his evaluation as an expert witness for the Burzynski side in the form of a detailed eight-page letter dated February 19, 1997 to the judge in Dr. Burzynski's case, the Hon. Sim Lake.

Dr. Burdick reviewed the case records of all the brain cancer patients who were included in Burzynski's FDA approved CAN-1 trial initiated in February, 1996. The purpose of the review was to have an independent oncologist critically examine these records to ascertain the veracity of the results and the toxicity of the treatment as compared to the current standard treatment.

Burdick carefully discusses the 17 cases that were submitted for his review. Since he is a medical oncologist, evaluation of the radiological evidence was carried out by another prominent doctor in the Washington, D.C. area. These 17 represented the "responders" from a total of 40 patients receiving antineoplaston therapy at that time.

Dr. Burdick reports that in the 17 patients, there were 7 complete remissions in 6 patients. That is because included among these was one patient who had two complete remissions: he discontinued antineoplastons and the tumor grew back. He then resumed antineoplastons and had a second complete remission. In addition, there were 9 partial remissions and 2 stabilizations.

Dr. Burdick wrote, "The average duration of antineoplastons necessary to obtain a complete remission was 10 months, with a range of 2 to 20 months. The average duration of therapy with antineoplastons necessary to obtain a partial response was 8 months, with a range of 1 to 14 months. The average duration of complete remissions is 16+ months with all six complete remissions continuing to remain in remission to the best of my knowledge through January 1, 1997."


The complete responders included a 47-year old woman with a glioblastoma; a 14-year-old girl also with glioblastoma; a 4-year-old boy with a medulloblastoma; a 47-year-old man with a malignant meningioma; and a 63-year old man with an anaplastic astrocytoma.

In conclusion, Dr. Burdick wrote that the judge that he was "very impressed with the number of complete and partial responses that I have seen here." He compared these responses to the dismal results he has seen in the course of his long career. "The responses here are also far in excess of any prior series of patients published in the medical literature."

Even after Dr. Schellinger downgraded two of the group of 17 from partial remission to stable disease, the results astonished the experienced doctor.

"Thus the response rate here is an astounding 33 percent with a complete remission rate of 15 percent. Such remission rates are far in excess of anything that I or anyone else has seen since research work on brain tumors began."


Dr. Burdick also deals with the often heard allegation that Burzynski's responses are due to the residual effects of conventional therapy. "It is very clear that the responses here are due to antineoplaston therapy and are not due to surgery, radiation or standard chemotherapy." In every case, antineoplaston therapy was only initiated two months or more after the last treatment with chemotherapy or radiation."[B]y consensus any benefit from chemotherapy or radiation occurs within two months of the cessation of these modalities of treatment or not at all. This insures that any delays in response to either of those two modalities cannot be interpreted as a response to antineoplaston therapy."

The Seattle doctor further cautions that antineoplaston therapy must be maintained over a longer period of time that oncologists may be used to with cytotoxic agents. "It is very clear that oftentimes responses are slow to develop in these tumors, despite almost daily therapy with antineoplastons and that when antineoplaston therapy is stopped tumors may regrow within a few months."


"The duration of these responses is long and meaningful," he states. "It is also clear that although there is some toxicity associated with antineoplastons, it does not appear life threatening in this small sample of patients." Although the doctor does not spell out the alleged "toxicity" of antineoplastons, there have been other anecdotal reports of edema, due to the high volume of liquid which must be injected into the patient in the course of the treatment.

This experienced physician concludes, "Research needs to continue on these very promising agents. We need to know such things as the optimal dose of these agents, the optimal route of administration, the optimal duration of treatment and many other details too numerous to mention."

The irony in all this is that Judge Sim Lake himself has precluded any discussion of the efficacy of the treatment in Burzynski's trial. Thus, everything that Dr. Burdick writes could be true--and Lake could thoroughly agree with it--and yet he could still sentence Dr. Burzynski to life imprisonment this spring. He would thereby annihilating one of the most promising treatments in the United States--and the hopes of 400 patients who believe it is essential for their survival.

--Ralph W. Moss, Ph.D.

Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.

Home - Moss reports - Coronavirus - Free Image Hosting - Books - Contact - Order - News - Members - Chronicles - FAQ - Free email newsletter